Americans Fill Prescriptions Every Month, and $90,000 Across These 3 Drugmakers Pays $3,650 a Year
Yahoo! Finance ·
Key points
- An illustrative $30,000 stake in each of Pfizer, Bristol Myers Squibb, and Merck yields about $3,650 annually, totaling 4.06% blended income on $90,000 invested.
- Pfizer provides the largest annual income among the three due to a higher dividend and broader product mix, even as it contends with patent losses for Ibrance and Xtandi in 2027 and shrinking COVID-related revenue.
- Bristol Myers Squibb's dividend supports $2.52 per year per share from a $0.63 quarterly payout, aided by Eliquis despite Revlimid and Pomalyst facing sharp declines from generics;
- Merck offers the lowest yield but has a track record of raising its dividend; its Keytruda patent risk weighs on the long-term income outlook, with expirations beginning in 2028.
- All three depend on upcoming pipeline outcomes to sustain payouts: Pfizer’s obesity drug berobenatide expected approvals around 2028; Bristol Myers’ mezigdomide decision is due May 13, 2027; Merck is expanding sac-TMT into more cancer indications.
- Dividend reliability is framed as contingent on pipeline success; the article notes that none of these dividends is guaranteed and a weaker pipeline could erode the current math.
Summary
The piece analyzes how three big pharma dividend stocks—Pfizer, Bristol Myers Squibb, and Merck—offer roughly $3,650 yearly income from a $90,000 investment, reflecting a blended yield around 4%. Demand for patented drugs provides steady cash flow, but a looming patent cliff threatens future payouts as key drugs lose protection and face generics. Each company shows a different risk/return profile: Pfizer carries the highest yield aided by diverse products; Bristol Myers Squibb faces declines in several drugs but still pays a solid dividend; Merck offers the smallest current payout but maintains a growth trajectory while grappling with Keytruda’s 2028 patent expiration. The analysis emphasizes that pipeline strength will determine whether these yields endure, and notes that dividends are not guaranteed. Looking ahead, the path depends on regulatory approvals and new drugs to replace expiring patents.
This summary was written with AI. The full story has every detail.